Their research indicates that Mir34a suppresses PDAC growth through controlling the immunological environment of the tumor, suggesting that reactivating Mir34a could be a helpful therapeutic strategy for slowing the disease’s progression [45]. Here, MIR34A is linked to neoplasm.